Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) Departure of Chief Financial Officer.
On April 14, 2021, Amol Chaubal notified Quanterix Corporation (the "Company")
of his resignation as Chief Financial Officer and Treasurer, effective May 11,
2021. Mr. Chaubal's resignation is not a result of any disagreement with the
Company or any matter relating to financial policies or procedures.
(c) Appointment of Interim Chief Financial Officer.
The Company has appointed Shawn Stetson to serve as Interim Chief Financial
Officer and Treasurer effective upon Mr. Chaubal's resignation. In this role,
Mr. Stetson will also serve as the Company's principal financial officer and
principal accounting officer.
There are no family relationships between Mr. Stetson and any of the Company's
directors, executive officers or persons nominated or chosen to be directors or
executive officers.
Mr. Stetson, age 44, has held a number of financial leadership roles in the
medical and technology industries. He has served as the Company's Senior
Director, Corporate Controller since July 2020 and as the Company's Corporate
Controller and Director, Accounting and Finance from June 2019 to July 2020. He
served as Associate Director and Corporate Controller of Nightstar Therapeutics,
a publicly traded clinical-stage gene therapy company focused on developing and
commercializing novel treatments for patients suffering from rare inherited
retinal diseases, from March 2019 until its acquisition by Biogen in June 2019.
From October 2017 to March 2019, he served as Corporate Controller for Novomer,
Inc., a leading developer of chemical conversion technology. From February 2012
to October 2017, he served in finance and accounting management roles, including
Assistant Controller and Financial Reporting Manager, at Cynosure, Inc., a
publicly traded developer and manufacturer of aesthetic and medical treatment
systems. Earlier in his career, Mr. Stetson held various positions of increasing
responsibility in the audit practice at Ernst & Young, LLP. Mr. Stetson, a
certified public accountant, holds a Master of Accounting and Master of Business
Administration from Northeastern University and a Bachelor of Arts degree from
Bowdoin College.
In connection with his appointment, Mr. Stetson will receive an equity award
having total value of $150,000 consisting of 70% stock options and 30%
restricted stock units ("RSUs") as determined on a unit basis, based on the
Company's standard valuation methodologies as of May 11, 2021. The award will
vest over a four-year period beginning on May 11, 2021, with one-fourth of the
options and RSUs vesting on the first anniversary of such date and the remainder
vesting in 36 equal installments at the end of each month thereafter, provided
that he remains with the Company as of the applicable vesting date.
Other than compensation solely resulting from his employment by the Company,
there have been no transactions, since the beginning of the Company's last
fiscal year, or any currently proposed transaction, in which the Company was or
is to be a participant, in which Mr. Stetson had or will have a direct or
indirect material interest.
© Edgar Online, source Glimpses